Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study

被引:42
|
作者
Syrigos, Konstantinos [1 ]
Grapsa, Dimitra [1 ]
Sangare, Rabiatou [2 ]
Evmorfiadis, Ilias [2 ]
Larsen, Annette K. [2 ]
Van Dreden, Patrick [3 ]
Boura, Paraskevi [1 ]
Charpidou, Andriani [1 ]
Kotteas, Elias [1 ]
Sergentanis, Theodoros N. [4 ]
Elalamy, Ismail [2 ,5 ]
Falanga, Anna [6 ,7 ]
Gerotziafas, Grigoris T. [2 ,5 ]
机构
[1] Univ Athens, Dept Med 3, Oncol Unit, Sch Med,Sotiria Gen Hosp, Athens, Greece
[2] Sorbonne Univ, Fac Med, Ctr Rech St Antoine, Canc Biol & Therapeut,INSERM,U938,IUC, Paris, France
[3] Diagnost Stago, Clin Res Dept, Gennevilliers, France
[4] Hop Univ Est Parisien, Hop Tenon, AP HP, Serv Hematol Biol, Paris, France
[5] Univ Athens, Sch Med, Alexandra Hosp, Dept Clin Therapeut, Athens, Greece
[6] ASST Papa Giovanni XXIII, Dept Immunohematol & Transfus Med, Bergamo, Italy
[7] ASST Papa Giovanni XXIII, Hemostasis & Thrombosis Ctr, Bergamo, Italy
关键词
Lung cancer; Venous thromboembolism; Thrombin generation; Cancer-associated thrombosis; Risk assessment model; PATIENTS RECEIVING CHEMOTHERAPY; VENOUS THROMBOEMBOLISM VTE; PREDICTION; VALIDATION; SCORE; PROPHYLAXIS; ISSUES;
D O I
10.1634/theoncologist.2017-0530
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The aim of this prospective study was to identify the most clinically relevant hypercoagulability biomarkers in lung adenocarcinoma patients for elaboration of an improved risk assessment model (RAM) for venous thromboembolism (VTE). Subjects, Materials, and Methods Results One hundred fifty ambulatory patients with lung adenocarcinoma were prospectively enrolled. Thrombin generation, procoagulant phospholipid-dependent clotting time (Procoag-PPL), tissue factor activity (TFa), factor VIIa (FVIIa), factor V (FV), antithrombin, D-Dimers, P-selectin, and heparanase levels were assessed in platelet-poor plasma at inclusion (baseline) and at the end of the third chemotherapy cycle (third chemotherapy). Cox regression analysis was used to identify independent VTE predictors. At baseline, patients had significantly attenuated thrombin generation, shorter Procoag-PPL, higher levels of TFa, D-Dimers, and heparanase, and lower levels of FVIIa and P-selectin, compared with controls. A significant increase in Procoag-PPL, FV, and FVIIa and a decrease of P-selectin levels were observed between baseline and third chemotherapy. Hospitalization within the last 3 months prior to assessment, time since cancer diagnosis less than 6 months, mean rate index (MRI) of thrombin generation, and Procoag-PPL were independently associated with symptomatic VTE. Accordingly, a prediction model including Procoag-PPL and MRI showed significant discriminating capacity (area under the curve: 0.84). Conclusion Implications for Practice Ambulatory patients with lung adenocarcinoma may display pronounced blood hypercoagulability due to decreased Procoag-PPL, increased endothelial cell activation, and increased degradation of fibrin. Incorporation of Procoag-PPL and MRI of thrombin generation may improve the accuracy of a VTE-RAM in the above setting.
引用
收藏
页码:1372 / 1381
页数:10
相关论文
共 50 条
  • [1] Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Newly Diagnosed Chemotherapy Naive Patients with Multiple Myeloma at Risk for Cancer-Associated Thrombosis. The Observational ROADMAT-CAT-MM Study
    Fotiou, Despina
    Sergentanis, Theodoros
    Papageorgiou, Loula
    Gavriatopoulou, Maria
    Psaltopoulou, Theodora
    VanDreden, Patrick
    Larsen, Annette
    Elalamy, Ismail
    Kastritis, Efstathios
    Stamatelopoulos, Kimon
    Terpos, Evangelos
    Dimopoulos, Meletios
    Gerotziafas, Grigoris
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S235 - S236
  • [2] Evaluation of cancer-associated thrombosis risk in patients with lung adenocarcinoma using the COMPASS-CAT risk assessment model
    Chrysanthidis, Miltiadis
    Charpidou, Andriani
    Dimakakos, Evangelos
    Grapsa, Dimitra
    Bakakos, Petros
    Stratakos, Grigorios
    Syrigos, Konstantinos
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [3] Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model
    Sud, Rohit
    Khorana, Alok A.
    THROMBOSIS RESEARCH, 2009, 123 : S18 - S21
  • [4] Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score
    Connolly, Gregory C.
    Khorana, Alok A.
    THROMBOSIS RESEARCH, 2010, 125 : S1 - S7
  • [5] Public Awareness on Cancer-Associated Thrombosis among the Greek Population: First Findings from the ROADMAP-CAT Awareness Study
    Souliotis, Kyriakos
    Golna, Christina
    Nikolaidi, Sofia
    Dreden, Patrick V.
    Vatheia, Georgia
    Gerotziafas, Grigoris T.
    TH OPEN, 2022, 06 (02) : e89 - e95
  • [6] In Search of the Appropriate Anticoagulant-Associated Bleeding Risk Assessment Model for Cancer-Associated Thrombosis Patients
    Poenou, Geraldine
    Toledano, Emmanuel
    Helfer, Helene
    Plaisance, Ludovic
    Happe, Florent
    Versini, Edouard
    Diab, Nevine
    Djennaoui, Sadji
    Mahe, Isabelle
    CANCERS, 2022, 14 (08)
  • [7] Derivation of Prediction Model for Treatment Failure Risk in Multiple Myeloma Patients Based on Biomarkers of Hypercoagulability. The Prospective Observational ROADMAP-MM-CAT Study
    Gerotziafas, Grigoris
    Fotiou, Despina
    Sergentanis, Theodoros
    Papageorgiou, Loula
    Rousseau, Aurelie
    Van Dreden, Patrick
    Elalamy, Ismail
    Larsen, Annette
    Falanga, Anna
    Terpos, Evangelos
    Mohty, Mohamad
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S323 - S323
  • [8] Cancer-Associated Thrombosis: A Clinical Scoping Review of the Risk Assessment Models Across Solid Tumours and Haematological Malignancies
    Mosaad, Manar
    Elnaem, Mohamed Hassan
    Cheema, Ejaz
    Ibrahim, Ismail
    Ab Rahman, Jamalludin
    Kori, Ahlam Naila
    Hin, How Soon
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 3881 - 3897
  • [9] Prospective Assessment of Biomarkers of Hypercoagulability for the Identification of Patients With Severe Coronary Artery Disease. The ROADMAP-CAD Study
    Gerotziafas, Grigoris T.
    Zografos, Theodoros
    Pantos, Ioannis
    Lefkou, Eleftheria
    Carlo, Audrey
    Fareed, Jawed
    Van Dreden, Patrick
    Katritsis, Demosthenes
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2020, 26
  • [10] Optimal authoritative risk assessment score of Cancer-associated venous thromboembolism for hospitalized medical patients with lung Cancer
    Xiong, Wei
    Zhao, Yunfeng
    Du, He
    Wang, Yanmin
    Xu, Mei
    Guo, Xuejun
    THROMBOSIS JOURNAL, 2021, 19 (01)